Home » Stocks » VYNE

VYNE Therapeutics, Inc. (VYNE)

Stock Price: $3.50 USD 0.10 (2.94%)
Updated May 12, 2021 4:00 PM EDT - Market closed
After-hours: $3.40 -0.10 (-2.86%) May 12, 7:56 PM
Market Cap 177.28M
Revenue (ttm) 23.36M
Net Income (ttm) -235.89M
Shares Out 51.39M
EPS (ttm) -5.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 12
Last Price $3.50
Previous Close $3.40
Change ($) 0.10
Change (%) 2.94%
Day's Open 3.39
Day's Range 3.28 - 3.55
Day's Volume 1,095,025
52-Week Range 1.30 - 11.20

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

The drugmaker reported disappointing Q1 results.

6 days ago - The Motley Fool

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 7.50% and -18.85%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

6 days ago - Zacks Investment Research

Conference call and live webcast today at 8:30 am Eastern Time Conference call and live webcast today at 8:30 am Eastern Time

6 days ago - GlobeNewsWire

BRIDGEWATER, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and part...

2 months ago - GlobeNewsWire

VYNE Therapeutics Inc. (VYNE) delivered earnings and revenue surprises of 14.00% and -12.17%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Conference call and live webcast to discuss financial results and new FMX114 program in atopic dermatitis today, Thursday, March 4, 2021, at 8:30 am Eastern Time Conference call and live webcast to disc...

2 months ago - GlobeNewsWire

BRIDGEWATER, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present and part...

2 months ago - GlobeNewsWire

Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. Some insiders have been taking advantage of secondary offerings recently.

Other stocks mentioned: HOG, TXN, ADS, BDGE, BRO, EVLO, MSM ...
3 months ago - Benzinga

BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct offerin...

3 months ago - GlobeNewsWire

This biotech stock is jumping, but what should investors expect from its new skincare treatments?

3 months ago - The Motley Fool

BRIDGEWATER, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”),  today announced that it has entered into definitive agreements with institutional a...

3 months ago - GlobeNewsWire

Vyne Therapeutics (VYNE) stock is taking off on Wednesday as investors take an interest in the pharmaceutical company on recent news. The post VYNE Stock: 13 Things to Know About Vyne Therapeutics as Sh...

3 months ago - InvestorPlace

BRIDGEWATER, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced the execution of a contract with a major PBM for its novel AMZEEQ® (m...

3 months ago - GlobeNewsWire

Company on track to initiate the TRILOGY Phase 3 program in 2021 Company on track to initiate the TRILOGY Phase 3 program in 2021

4 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Dec. 16, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to...

4 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will participate in a ...

5 months ago - GlobeNewsWire

VYNE Therapeutics (VYNE) CEO David Domzalski on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Vyne Therapeutics is executing well, successfully launching 2 differentiated dermatology products this year.

7 months ago - Seeking Alpha

BRIDGEWATER, N.J., Oct. 7, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced a coverage update for its novel ZILXI™ (minocycline) topical foam, 1.5%. Z...

7 months ago - PRNewsWire

BRIDGEWATER, N.J., Oct. 1, 2020 /PRNewswire/ -- VYNE Therapeutics Inc. (Nasdaq: VYNE) ("VYNE" or the "Company") today announced that its novel ZILXI™ (minocycline) topical foam, 1.5% will be available o...

7 months ago - PRNewsWire

ZILXI is the First FDA Approved Minocycline Product for the Treatment of Inflammatory Lesions of Rosacea in Adults

7 months ago - GlobeNewsWire

Since the time of my last article, Vyne's market cap has dropped from $330 million to just $285 million.

7 months ago - Seeking Alpha

Live webinar on October 1st to feature presentations by 3 KOLs in dermatology Live webinar on October 1st to feature presentations by 3 KOLs in dermatology

7 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Sept. 14, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the Board of Directors of the Company appointed Mr. Patrick G...

7 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that David Domzalski, Chief Executive Officer, will present at the...

Other stocks mentioned: MNLO
8 months ago - GlobeNewsWire

BRIDGEWATER, N.J., Sept. 8, 2020 /PRNewswire/ -- VYNE Therapeutics Inc.

Other stocks mentioned: MNLO
8 months ago - PRNewsWire

Menlo Therapeutics' (MNLO) CEO David Domzalski on Q2 2020 Results - Earnings Call Transcript

Other stocks mentioned: MNLO
9 months ago - Seeking Alpha

Menlo Therapeutics Inc. (MNLO) delivered earnings and revenue surprises of -476.19% and 472.94%, respectively, for the quarter ended June 2020.

Other stocks mentioned: MNLO
9 months ago - Zacks Investment Research

MNLO's enterprise valuation at $1.70/share is

Other stocks mentioned: MNLO
9 months ago - Seeking Alpha

Menlo Therapeutics: Strong Amzeeq Launch, Recent Zilxi Approval And Positive FCD105 Results Point To Growth Ahead

Other stocks mentioned: MNLO
11 months ago - Seeking Alpha

The pricing of the biotech's stock offering weighed on shares.

Other stocks mentioned: MNLO
11 months ago - The Motley Fool

Menlo Therapeutics Inc (NASDAQ: MNLO) shares are trading lower on Friday, after the company reported a common stock offering of 27.05 million shares at $1.85 per share.

Other stocks mentioned: MNLO
11 months ago - Benzinga

BRIDGEWATER, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapie...

Other stocks mentioned: MNLO
11 months ago - GlobeNewsWire

BRIDGEWATER, N.J., June 04, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (“Menlo”) (Nasdaq: MNLO), a specialty pharmaceutical company focused on developing and commercializing proprietary therapie...

Other stocks mentioned: MNLO
11 months ago - GlobeNewsWire

Menlo Therapeutics: Dip In Share Price Post Zilxi Approval Presents A Good Buying Opportunity

Other stocks mentioned: MNLO
11 months ago - Seeking Alpha

BRIDGEWATER, N.J., May 29, 2020 /PRNewswire/ -- Menlo Therapeutics Inc. (Nasdaq: MNLO) ("Menlo" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietar...

Other stocks mentioned: MNLO
11 months ago - PRNewsWire

ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults ZILXI™ Now Approved for Inflammatory Lesions of Rosacea in Adults

Other stocks mentioned: MNLO
11 months ago - GlobeNewsWire

Menlo Therapeutics (MNLO) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Other stocks mentioned: MNLO
11 months ago - Zacks Investment Research

Should The FDA Approve Menlo Therapeutics Latest Therapy Shares Should Do Well

Other stocks mentioned: MNLO
11 months ago - Seeking Alpha

Menlo Therapeutics' (MNLO) CEO Dave Domzalski on Q1 2020 Results - Earnings Call Transcript

Other stocks mentioned: MNLO
1 year ago - Seeking Alpha

Menlo Therapeutics Inc (MNLO) delivered earnings and revenue surprises of -90.00% and -20.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Other stocks mentioned: MNLO
1 year ago - Zacks Investment Research

As of late, it has definitely been a great time to be an investor in Menlo Therapeutics Inc. (MNLO).

Other stocks mentioned: MNLO
1 year ago - Zacks Investment Research

Menlo (MNLO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Other stocks mentioned: MNLO
1 year ago - Zacks Investment Research

Transaction provides non-dilutive capital including $10M up-front Transaction provides non-dilutive capital including $10M up-front

Other stocks mentioned: MNLO
1 year ago - GlobeNewsWire

There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.

Other stocks mentioned: EVRI, GERN, MNLO, ORBC, PLUG, RMTI, SELB
1 year ago - InvestorPlace

Conference call today at 8.30am EDT Conference call today at 8.30am EDT

Other stocks mentioned: MNLO
1 year ago - GlobeNewsWire

BRIDGEWATER, N.J., April 02, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprieta...

Other stocks mentioned: MNLO
1 year ago - GlobeNewsWire

BRIDGEWATER, N.J., March 24, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprieta...

Other stocks mentioned: MNLO
1 year ago - GlobeNewsWire

BRIDGEWATER, N.J., March 20, 2020 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a biopharmaceutical company focused on developing and commercializing proprieta...

Other stocks mentioned: MNLO
1 year ago - GlobeNewsWire

About VYNE

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. The company offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older; and ZILXI for the treatment of inflammation lesions of papulopustular rosacea in adults. It is also developing FCD105, a topical combination foam that has completed Phase II clinical trials for the treatment of moderate-to-severe acne vul... [Read more...]

Industry
Biotechnology
IPO Date
Jan 25, 2018
Stock Exchange
NASDAQ
Ticker Symbol
VYNE
Full Company Profile

Financial Performance

In 2020, VYNE's revenue was $20.99 million, an increase of 4,638.83% compared to the previous year's $443,000. Losses were -$255.57 million, 168.5% more than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for VYNE stock is "Strong Buy." The 12-month stock price forecast is 11.86, which is an increase of 238.86% from the latest price.

Price Target
$11.86
(238.86% upside)
Analyst Consensus: Strong Buy